Nimbus's AI-Crafted Drug Aims to Heal the Gut in IBD Treatment

BOSTON, MA – February 17, 2026 – In a promising development for millions suffering from inflammatory bowel disease (IBD), Boston-based Nimbus Therapeutics is poised to unveil new data on a novel drug candidate that employs a unique dual-action strategy: simultaneously suppressing inflammation and promoting tissue repair. The company will present its findings on a highly selective salt-inducible kinase 2 (SIK2) inhibitor at the upcoming 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) in Stockholm.

This new therapeutic approach, powered by artificial intelligence and advanced computational chemistry, targets a key inflammatory pathway with unprecedented precision. For patients navigating the debilitating cycles of Crohn’s disease and ulcerative colitis, the prospect of a safe, effective oral medication that not only manages symptoms but also heals the gut lining could represent a significant leap forward in treatment.

The Science of Selectivity: A Dual-Action Approach

At the heart of Nimbus's innovation lies a deep understanding of a complex family of enzymes known as salt-inducible kinases (SIKs). This family comprises three isoforms—SIK1, SIK2, and SIK3—that regulate cellular responses to stress and inflammation. While they are related, they play distinct roles, and inhibiting them indiscriminately can be problematic. For instance, broad inhibition of SIK1 has been linked to potential cardiovascular side effects, while loss of SIK3 function can lead to bone defects.

Nimbus’s research zeroes in on SIK2, a key amplifier of pro-inflammatory signals in myeloid cells, a type of immune cell abundant in the inflamed gut tissue of IBD patients. By selectively blocking SIK2, the company's drug candidate effectively turns down the volume on harmful pro-inflammatory cytokines like TNF-α and IL-6.

However, the true novelty of this approach is what happens next. Unlike other anti-inflammatory drugs, the selective inhibition of SIK2 also triggers a unique and beneficial secondary effect: it boosts the production of interleukin-10 (IL-10), a powerful anti-inflammatory and tissue-repair factor. This dual mechanism of suppressing inflammation while actively promoting mucosal healing is a key differentiator in a field where achieving deep, lasting tissue repair remains a significant challenge.

"This body of data validates that highly selective SIK2 inhibition achieves robust efficacy across preclinical and human ex vivo models through a dual mechanism of suppressing inflammation and promoting mucosal healing," said Peter Tummino, Ph.D., President of Research and Development at Nimbus. He emphasized that this approach could offer an improved safety profile compared to therapies targeting broader SIK inhibition.

A New Hope for Patients with Inflammatory Bowel Disease

The current treatment landscape for IBD, which includes Crohn's disease and ulcerative colitis, is fraught with challenges. While existing biologics and small molecules can be effective, a significant number of patients either do not respond, lose response over time, or suffer from burdensome side effects. Furthermore, many of the most potent therapies require injections or intravenous infusions, adding a significant treatment burden to patients' lives.

The search for a convenient, oral therapy that combines high efficacy with a strong safety profile is a holy grail in IBD research. Nimbus's SIK2 inhibitor program is positioned to address these unmet needs directly. By promoting mucosal healing—the physical repair of the intestinal lining—the therapy aims to deliver more than just symptom relief. Achieving this level of deep, histological remission is increasingly seen by clinicians as crucial for preventing long-term complications, reducing hospitalizations, and avoiding the need for surgery.

The data to be presented at the ECCO congress will provide the first public look at the drug's performance in models of the disease. Two poster presentations, led by Nimbus scientists Yanbo Zhang, Ph.D., and Scott Daigle, will detail findings from preclinical colitis models and human ex vivo models of ulcerative colitis, respectively, providing a comprehensive picture of the drug's dual anti-inflammatory and mucosal repair capabilities.

AI-Powered Precision: Redefining Drug Discovery

The development of such a highly targeted molecule was no accident. It is the direct result of Nimbus's core strategy: leveraging AI-enhanced computational chemistry to design drugs against well-validated but notoriously "difficult-to-drug" targets. Using sophisticated structure-based drug design and machine learning algorithms, the company’s platform can rapidly design and optimize compounds with very specific properties.

In the case of its SIK2 program, this AI-driven approach enabled the creation of inhibitors with greater than 300-fold selectivity for SIK2 over its SIK1 and SIK3 cousins. This remarkable precision is what allows the drug to deliver its therapeutic effects while steering clear of the toxicities associated with the other isoforms, a critical factor for any medication intended for long-term use in a chronic condition.

This strategy extends across Nimbus's entire pipeline, which includes programs in oncology and metabolic diseases. For example, its Werner syndrome helicase (WRN) inhibitor, currently in Phase 1/2 clinical trials for certain cancers, also emerged from this platform designed to conquer challenging biological targets. The SIK2 program serves as another powerful proof-of-concept for the company's high-tech approach to drug discovery.

Navigating the Competitive Landscape and Future Steps

While the IBD market is crowded with therapies from pharmaceutical giants targeting established pathways like JAK, TNF, and IL-23, Nimbus is carving out a distinct niche. By pursuing a novel mechanism of action with its selective SIK2 inhibitor, the company is not creating a "me-too" drug but is pioneering a potentially first-in-class therapeutic category.

Success at the ECCO congress will build crucial momentum for the program. The abstracts, already available in a supplement to the Journal of Crohn's and Colitis, have set the stage for what could be one of the more talked-about preclinical programs at the conference. Following the presentation, the full posters will be made available on the company's website, allowing the broader scientific community to scrutinize the data.

The ultimate test, however, lies ahead. According to Dr. Tummino, the strong preclinical and translational data provide a solid foundation for the next pivotal step. The company is now preparing to advance its novel SIK2 program toward first-in-human clinical studies in the coming months, marking a critical transition from the lab to the clinic, where its true potential to transform patients' lives will be evaluated.